# SAB Biotherapeutics, Inc.: Form SCHEDULE 13D/A, filed Mar 11, 2026

- Company: [SAB Biotherapeutics, Inc.](/companies/sabs.md) (CIK 1833214)
- Form: SCHEDULE 13D/A
- Filed: 2026-03-11
- Accepted by EDGAR: Mar 11, 2026, 16:43 ET
- Period: not reported
- Accession: 0001346824-26-000072
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1833214/000134682426000072/xslSCHEDULE_13D_X01/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1833214/000134682426000072/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1833214/000134682426000072/xslSCHEDULE_13D_X01/primary_doc.xml

Filed Mar 11, 2026.
Source: SEC EDGAR, the filing index for accession 0001346824-26-000072. Last ingested by Listed: Nov 5, 2026, 12:06 ET. No prices; not investment advice.
